KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Operating Margin (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Operating Margin data on record, last reported at 221.58% in Q4 2025.

  • For Q4 2025, Operating Margin fell 10716.0% year-over-year to 221.58%; the TTM value through Dec 2025 reached 159.5%, down 10605.0%, while the annual FY2025 figure was 159.5%, 10605.0% down from the prior year.
  • Operating Margin reached 221.58% in Q4 2025 per AQST's latest filing, down from 89.63% in the prior quarter.
  • Across five years, Operating Margin topped out at 0.27% in Q2 2024 and bottomed at 325.85% in Q2 2021.
  • Average Operating Margin over 5 years is 101.59%, with a median of 84.5% recorded in 2022.
  • The widest YoY moves for Operating Margin: up 28456bps in 2021, down -40485bps in 2021.
  • A 5-year view of Operating Margin shows it stood at 105.33% in 2021, then grew by 5bps to 100.29% in 2022, then surged by 70bps to 29.62% in 2023, then crashed by -286bps to 114.43% in 2024, then crashed by -94bps to 221.58% in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Margin were 221.58% in Q4 2025, 89.63% in Q3 2025, and 113.65% in Q2 2025.